News

NuPathe said that the first trial compared the pharmacokinetics of Zelrix in healthy elderly volunteers to healthy young adult volunteers and the pharmacokinetics of Zelrix applied to the

As per the terms of the agreement, Novartis is expected to pay a $45m upfront fee to ImmunoGen for exclusive rights to use ImmunoGen’s Targeted Antibody Payload (TAP)

MorphoSys is expected to provide relevant antigen and antibody molecules, while Proteros is expected to provide advanced x-ray technology and computational chemistry know-how. MorphoSys and Proteros claimed that

AZ-004 is being developed for the treatment of agitation in patients with schizophrenia or bipolar disorder. In the CRL, the FDA has stated that their primary clinical safety

Vickers will be responsible for leading global R&D for Shire HGT and for establishing the strategic direction of the company’s pipeline. Vickers will report to Sylvie Gregoire, president

In the letter, the FDA discussed a number of topics, including the need for additional clinical studies, the appropriate patient population, methods for ensuring safe use, and the

de Garidel started his career in 1983 with the Eli Lilly pharmaceutical Group where he held various roles, mainly finance related, firstly in France, then in the US

As per the terms of the agreement, Lundbeck is expected to pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to

Daiichi Sankyo, the holder of the investigational new drug application for ARQ 197 and ArQule’s partner for the development of the compound, will conduct the Phase 3 trial,